SpaceX Is Skipping the Standard 180-Day Insider Lock-Up — Here's What That Means for New Shareholders

SpaceX Is Skipping the Standard 180-Day Insider Lock-Up — Here's What That Means for New Shareholders

When most companies go public, insiders are locked out of selling for 180 days — a guardrail designed to signal confidence and limit early sell pressure. According to reporting cited on r/wallstreetbets, SpaceX is taking a different path: a phased release structure that lets pre-IPO investors sell portions of their holdings in the weeks and months immediately following the IPO, well before a traditional lock-up would expire.

The company's stated rationale is structural. Rather than one large unlock date that could flood the market with supply all at once, the phased approach spreads selling pressure over time. There's a second incentive too: a higher and faster-growing float — the pool of shares available for public trading — could accelerate SpaceX's eligibility for inclusion in major indices like the Nasdaq 100, which would trigger automatic buying from index funds and ETFs.

The retail investor community isn't buying the framing. On r/wallstreetbets, the top reactions ranged from blunt skepticism to darker conclusions — with commenters describing the structure as insiders planning their exit before retail investors can react. Whether the phased approach genuinely dampens volatility or simply redistributes it is a question the market will answer after the IPO closes.

Gobble's Take: A smoother unlock schedule is better than a cliff — but "better for the stock" and "better for late buyers" aren't always the same sentence.

Source: r/wallstreetbets

Abbott Labs Is Down 32% Over the Past Year. Analysts Still Rate It a Strong Buy.

Abbott Laboratories — the diversified healthcare company behind everything from continuous glucose monitors to infant formula — has watched its share price fall roughly 32% over the past year, according to a Yahoo Finance analysis. The decline reflects a confluence of pressures: a cut to its full-year 2026 adjusted earnings per share guidance, a revenue miss in Q1 2026, ongoing legal exposure tied to infant formula lawsuits, and the financial weight of its $23 billion acquisition of cancer diagnostics company Exact Sciences.

Despite those headwinds, Wall Street's analyst consensus remains a "Strong Buy," per the Yahoo Finance report. The average price target cited is $124.31, against a recent trading price of $88.82 — implying roughly 40% upside from current levels. The bullish case rests on Abbott's diversified portfolio, international revenue base, and Medical Devices segment, which reportedly posted 8.5% sales growth in Q1 2026. Analysts appear to view near-term integration costs and legal risk as already priced in, with longer-term growth drivers intact.

A 32% decline in a blue-chip name tends to attract attention — the debate now is whether this is a reset or a repricing.

Gobble's Take: The gap between an $88 price and a $124 target is either a value opportunity or a reminder that analyst targets can be slow to follow stocks downward — the source material doesn't resolve that, and neither should you.

Source: Yahoo Finance

QXO Is Trading at Less Than Half Its Median Analyst Target — With Losses to Match

QXO, a building products distribution company led by Chairman and CEO Brad Jacobs, has seen its share price weaken recently — and according to a Yahoo Finance valuation analysis, the gap between where it trades and where analysts think it should be is unusually wide. The stock was recently trading around $17.23, against a median analyst price target of $30.00, implying roughly 74% upside. Some targets reach as high as $50.00, per the report.

The bull case centers on Jacobs' track record in "roll-up" acquisitions and QXO's stated ambition to consolidate the fragmented building products distribution market — which the company characterizes as an $800 billion opportunity — targeting $50 billion in annual revenue within a decade. Acquisitions including TopBuild and Kodiak have driven revenue growth that the Yahoo Finance piece describes as up 12,716.3% year-over-year. The bear case is equally clear: QXO is currently operating at a loss, channeling capital into expansion rather than earnings, which creates the discount the analysis flags.

The wide spread between price and target reflects a company that analysts see as early-stage within a large market — with all the uncertainty that framing implies.

Gobble's Take: A 74% gap between price and target is either a screaming opportunity or a sign that the target needs to come down — the current losses make that distinction worth sitting with.

Source: Yahoo Finance

Quick Hits

• Ford, GM, Stellantis weekly scorecard: USA Today tracked how the three legacy automakers' stocks performed for the week ending May 22 — a snapshot worth watching as tariff uncertainty continues to weigh on the sector. USA Today
• InterDigital down 31% — buy signal or falling knife?: Trefis flagged the wireless technology licensor's steep decline as a potential dip-buying opportunity, with analysis weighing the company's patent licensing revenue against the size of the drop. Trefis

In Case You Missed It

Yesterday's top stories:

• Jensen Huang Told Investors to "Expect Nothing" from China — And Not One Approved H200 Chip Has Shipped
• Ubisoft Reports a Record €1.3 Billion Operating Loss for the Fiscal Year Ending March 2026